Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Buy
4,145
+1,975
+91% +$425K 0.65% 43
2026
Q1
$472K Hold
2,170
0.33% 82
2025
Q4
$496K Sell
2,170
-6
-0.3% -$1.37K 0.34% 80
2025
Q3
$504K Buy
2,176
+200
+10% +$40.7K 0.35% 83
2025
Q2
$367K Hold
1,976
0.29% 90
2025
Q1
$414K Buy
1,976
+37
+2% +$7.19K 0.33% 79
2024
Q4
$345K Hold
1,939
0.28% 87
2024
Q3
$383K Hold
1,939
0.31% 82
2024
Q2
$333K Sell
1,939
-28
-1% -$4.64K 0.28% 81
2024
Q1
$358K Sell
1,967
-17
-0.9% -$2.93K 0.29% 78
2023
Q4
$307K Sell
1,984
-385
-16% -$56.1K 0.27% 87
2023
Q3
$353K Sell
2,369
-59
-2% -$8.66K 0.34% 72
2023
Q2
$327K Buy
+2,428
New +$356K 0.32% 77

Other funds holding ABBV

Exchange Bank's ABBV Position: Q2 2026 in Review

Exchange Bank increased its AbbVie (ABBV) stake by 91% in Q2 2026, buying an estimated $425K and bringing the position to 4,145 shares worth $1.04M. The position accounts for 0.65% of the portfolio, ranked #43.

Exchange Bank first reported a position in ABBV in Q2 2023 and has held it in 13 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Exchange Bank held 4,145 shares of AbbVie worth $1.04M as of Q2 2026.
  • Exchange Bank bought 1,975 AbbVie shares in Q2 2026, an estimated $425K.
  • AbbVie made up 0.65% of Exchange Bank's portfolio in Q2 2026, its #43 holding.
  • Exchange Bank first reported a position in AbbVie in Q2 2023 and has held it in 13 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Exchange Bank's 13F filing for Q2 2026, filed 9 Jul 2026.